Inogen
INGNNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $6.00 Prior regular-session close from the quote source.
- $5.69–$6.01 Regular-session low and high so far today.
- 286.1K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $5.05–$7.67 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own INGN if POC demand recovers with enough gross margin and cost discipline to end cash burn.
INGN price history
Loading recent earnings…
Investment thesis
What must happen next
The tank-to-portable-concentrator substitution problem remains strong enough that patients and oxygen providers continue choosing Inogen’s POCs over oxygen-tank delivery and stationary alternatives.HoldingMateriality: High
GAAP annual revenue increased from $315.7 million in FY2023 to $335.7 million in FY2024 and $348.7 million in FY2025. If this holds, revenue recovery has a real demand driver; if it breaks, Inogen is fighting a shrinking or commoditized niche rather than riding a structural substitution trend.
Watch: Major oxygen equipment providers standardize on lower-cost competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or other manufacturers instead of Inogen devices.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $315.7 million in FY2023 to $335.7 million in FY2024 and $348.7 million in FY2025.
Open source ↗Inogen’s products must remain differentiated enough in portability, performance, service, and clinical acceptance to avoid price-led commoditization of POCs and preserve device gross economics.HoldingMateriality: High
GAAP annual gross profit improved from $126.7 million in FY2023 to $154.7 million in FY2024. Durable gross economics determine whether growth creates value or merely adds low-margin volume.
Watch: Competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or lower-cost manufacturers match Inogen’s portability and reliability at materially lower price points.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit improved from $126.7 million in FY2023 to $154.7 million in FY2024.
Open source ↗The restructured operating model must let incremental POC and respiratory-product demand flow through the existing cost base instead of requiring another round of high sales, marketing, or support spending.HoldingMateriality: Medium
GAAP annual operating loss narrowed from $109.4 million in FY2023 to $42.5 million in FY2024 and $30.2 million in FY2025. This is the bridge from a viable product to an investable business: without operating leverage, shareholders fund losses even if demand is real.
Watch: Direct-to-consumer lead costs rise or referral channels deteriorate, forcing Inogen to spend materially more on customer acquisition to sustain demand.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed from $109.4 million in FY2023 to $42.5 million in FY2024 and $30.2 million in FY2025.
Open source ↗Inogen’s balance sheet must provide enough runway to complete the operating turnaround without dilutive financing or a forced strategic retrenchment.HoldingMateriality: Medium
Cash was $103.7 million at December 31, 2025. A turnaround with sufficient cash can compound for owners; a turnaround that runs out of cash transfers value to new capital providers.
Watch: Operating cash burn accelerates because price pressure, product support costs, or commercialization spending rise before revenue scales.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $103.7 million at December 31, 2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The tank-to-portable-concentrator substitution problem remains strong enough that patients and oxygen providers continue choosing Inogen’s POCs over oxygen-tank delivery and stationary alternatives. If this holds, revenue recovery has a real demand driver; if it breaks, Inogen is fighting a shrinking or commoditized niche rather than riding a structural substitution trend.
Inogen’s products must remain differentiated enough in portability, performance, service, and clinical acceptance to avoid price-led commoditization of POCs and preserve device gross economics. Durable gross economics determine whether growth creates value or merely adds low-margin volume.
The restructured operating model must let incremental POC and respiratory-product demand flow through the existing cost base instead of requiring another round of high sales, marketing, or support spending. This is the bridge from a viable product to an investable business: without operating leverage, shareholders fund losses even if demand is real.
Inogen’s balance sheet must provide enough runway to complete the operating turnaround without dilutive financing or a forced strategic retrenchment. A turnaround with sufficient cash can compound for owners; a turnaround that runs out of cash transfers value to new capital providers.
All standing thesis claims
Original report summary
POC demand recovers with enough gross margin and cost discipline to end cash burn.
Bull case and bear case
Bull case and bear case for Inogen
Where the evidence on Inogen stands: Holding on the latest evidence (Nov 7, 2026). Of its 4 thesis points, 4 holding.
Bull case: what the evidence supports
The tank-to-portable-concentrator substitution problem remains strong enough that patients and oxygen providers continue choosing Inogen’s POCs over oxygen-tank delivery and stationary alternatives.
Inogen’s products must remain differentiated enough in portability, performance, service, and clinical acceptance to avoid price-led commoditization of POCs and preserve device gross economics.
The restructured operating model must let incremental POC and respiratory-product demand flow through the existing cost base instead of requiring another round of high sales, marketing, or support spending.
Inogen’s balance sheet must provide enough runway to complete the operating turnaround without dilutive financing or a forced strategic retrenchment.
Bear case: what would count against it
Major oxygen equipment providers standardize on lower-cost competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or other manufacturers instead of Inogen devices.
Competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or lower-cost manufacturers match Inogen’s portability and reliability at materially lower price points.
Direct-to-consumer lead costs rise or referral channels deteriorate, forcing Inogen to spend materially more on customer acquisition to sustain demand.
Thesis-Break Engine
Thesis-break watch · Inogen
Loading the break-condition record for Inogen.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedCompleted an acquisition or disposition of assets.
Inogen filed an SEC 8-K on 2026-11-05: Completed an acquisition or disposition of assets. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Inogen filed an SEC 8-K on 2026-09-30: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Inogen filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Major oxygen equipment providers standardize on lower-cost competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or other manufacturers instead of Inogen devices.
- Competing POCs from CAIRE, Philips Respironics, Drive DeVilbiss, or lower-cost manufacturers match Inogen’s portability and reliability at materially lower price points.
- Direct-to-consumer lead costs rise or referral channels deteriorate, forcing Inogen to spend materially more on customer acquisition to sustain demand.
- Operating cash burn accelerates because price pressure, product support costs, or commercialization spending rise before revenue scales.
INGN news
Loading headlines…
Financial statements
INGN income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.